The calcium release channels (CRC)/ryanodine receptors of skeletal (Sk) and cardiac (C) muscle sarcoplasmic reticulum (SR) are hetero-oligomeric complexes with the structural formulas (ryanodine recepter (RyR)1 protomer) 4 (FKBP12) 4 and (RyR2 protomer) 4 (FKBP12.6) 4 , respectively, where FKBP12 and FKBP12.6 are isoforms of the 12-kDa receptor for the immunosuppressant drug FK506. The sequence similarity between the RyR protomers and FKBP12 isoforms is 63 and 85%, respectively. Using 35 S-labeled FKBP12 and 35 S-labeled FKBP12.6 as probes to study the interaction with CRC, we find that: 1) analogous to its action in skeletal muscle sarcoplasmic reticulum (SkMSR), FK506 (or analog FK590) dissociates FKBP12.6 from CSR; 2) both FKBP isoforms bind to FKBP-stripped SkMSR and exchange with endogenously bound FKBP12 of SkMSR; and 3) by contrast, only FKBP12.6 exchanges with endogenously bound FKBP12.6 or rebinds to FKBP-stripped CSR. This selective binding appears to explain why the cardiac CRC is isolated as a complex with FKBP12.6, whereas the skeletal muscle CRC is isolated as a complex with FKBP12, although only FKBP12 is detectable in the myoplasm of both muscle types. Also, in contrast to the activation of the channel by removal of FKBP from skeletal muscle, no activation is detected in CRC activity in FKBPstripped CSR. This differential action of FKBP may reflect a fundamental difference in the modulation of excitation-contraction coupling in heart versus skeletal muscle.
FK506 is a potent immunosuppressive drug that binds to a family of related intracellular receptors termed FK506-binding proteins, varying in size from 12 to 54 kDa. Among these FKBPs, 1 FKBP12 is the most abundant and is involved in mediating the immunosuppressive action of FK506 in T lymphocytes. All of the known FKBP family members display cis-trans peptidyl-prolyl isomerase (PPIase) activity that is inhibited by FK506 and a structurally related compound, rapamycin (1) . However, neither the immunosuppressive nor toxic side effects (including severe neuro-and nephrotoxicity) associated with FK506 therapy result from the inhibition of PPIase activity. Rather, the action of FK506 results from the specific inhibition of calcineurin by the FKBP12⅐drug complex. Calcineurin is a calcium-dependent protein phosphatase involved in the activation of T-lymphocytes (2) . FKBP12 is a mere bystander protein during T-cell activation that becomes involved in blocking activation after it binds FK506. To date, the only physiological function directly associated with FKBP12 is its tight binding to (3, 4) and modulation of the ryanodine receptor (RyR-1) or calcium release channel of skeletal muscle SR (5-10). The purified SkM CRC 2 isolated from the CHAPS-solubilized TC is a hetero-oligomeric complex, with the structural formula of (RyR-1 protomer) 4 (FKBP12) 4 (5) . Both FK506 and rapamycin bind to and dissociate FKBP12 from the SkM CRC (5) . Both the native and FKBP-stripped CRCs have similar unitary conductance and sensitivity to ruthenium red (6) . However, in comparison to the native SkM CRC, the FKBP-stripped channel is activated by lower concentrations of calcium or caffeine (5, 6) , displays, by single channel analysis, both longer mean open times and greater open probabilities (6) , and requires greater concentrations of magnesium for inactivation (10) . These effects are reversed upon rebinding human recombinant FKBP12. Thus, FKBP12 appears to stabilize a closed conformation of the RyR-1 channel from SR vesicles. Brillantes et al. (7) reported that the cloned RyR-1, expressed in either Sf9 cells or Xenopus oocytes, flickers equally between four different subconductance states, and that the addition of FKBP12 to the expressed channel converts this subconductance activity to the full conductance state observed in native channels. Ahern et al. (8) have also reported subconductance states of skeletal muscle CRC after treatment with FK506. In summary, some of the characteristics of the SkM CRC are conferred in part by FKBP12. The role of PPIase activity of FKBP12 in CRC function remains in question since both wild-type FKBP12 and PPIase-deficient mutants bind to and restore the net calcium loading rate of FKBP-stripped TC vesicles to comparable levels (10) .
We have recently characterized an exchange reaction between FKBP12, tightly bound to the SkM CRC of TC vesicles, with soluble 35 S-labeled FKBP12 (10) . The exchange rate is enhanced with increasing temperature from 0 to 37°C. The exchange is essentially negligible in the cold (0 -4°C) for several hours. At 37°C, the EC 50 for exchange is 0.30 M FKBP12, with a half-time of less than 5 min. The concentration of * This investigation was supported, in part, by National Institutes of Health Grants HL32711 and HL46681 (to S. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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We have reported that the cardiac calcium release channel/ ryanodine receptor (RyR-2) isolated from CHAPS-solubilized canine heart SR vesicles is tightly associated with FKBP-C (cardiac) (11) . This previously uncharacterized FKBP now appears to be identical to FKBP12.6, a novel FKBP12 isoform recently isolated, cloned, and characterized (12, 13) . FKBP-C (cardiac), isolated from the purified canine cardiac CRC, and FKBP12.6 share an identical N-terminal amino acid sequence that is distinct from FKBP12 and comigrate during SDS-polyacrylamide gel electrophoresis analysis with a relative mobility that is slightly slower than FKBP12 (11, 13) . Both FKBP12 and FKBP12.6 isoforms share many structural and functional similarities, including: 1) 85% amino acid sequence homology; 2) PPIase activity that is inhibited by either FK506 or rapamycin; and 3) ability when complexed with FK506 to inhibit calcineurin (12) . Furthermore, it has been demonstrated that FKBP12.6 and FKBP12 are equipotent inhibitors of calcineurindependent signaling pathways in Jurkat cells (13) . In summary, the two FKBP12 isoforms display nearly identical properties in every respect with one important exception; FKBP12.6, but not FKBP12, is tightly associated with the cardiac CRC of canine heart SR vesicles (13) , although only FKBP12 was detectable in the cardiac cytosolic fraction by Western blot analysis (11) .
In this study, the interaction between 35 S-labeled FKBP12 and 35 S-labeled FKBP12.6 with canine heart and rabbit skeletal muscle SR vesicles were studied by both the direct binding and exchange methodologies described previously (10) . We find a specificity for the cardiac RyR-2 to bind FKBP12.6 over FKBP12, whereas the skeletal muscle RyR-1 binds both FKBP12 isoforms with comparable affinity.
EXPERIMENTAL PROCEDURES
Materials-L-683,590, a structural and functional analogue of FK506 was obtained from Merck Research Laboratories. This analogue is referred to as FK590 and, in the literature, has been referred to by others as FK520.
35 S-Labeled and unlabeled FKBP12 (10) and FKBP12.6 were recombinantly expressed (13) . Isolation of SR from Cardiac and Skeletal Muscle-Cardiac microsomes (CSR) were isolated from canine heart as described by Chamberlain et al. (14) . The supernatant obtained from the microsome fraction of dog heart was used to analyze FKBP in the cytosol. TC vesicles of SR were isolated from rabbit skeletal muscle as described previously (15) . The R 3 fraction from the TC preparation was used in the comparative 35 S-labeled FKBP12 binding studies because, in comparison to the highly enriched R 4 TC fraction, which has higher concentration of high affinity ryanodine binding (of about 25 pmol ryanodine/mg protein), the concentration of high affinity ryanodine binding sites in the R 3 fraction (about 8 pmol/mg protein) was closer to that of the CSR (5.3 pmol/mg protein).
35 S-Labeled FKBP Exchange Studies-Assays for the exchange of bound FKBP12 for soluble 35 S-labeled FKBP12 were performed essentially as described previously (10) . Briefly, rabbit skeletal muscle SR and canine CSR vesicles (final concentration, 2.0 mg/ml) were incubated with 35 S-labeled FKBP12.6 (600 cpm/pmol) or 35 S-labeled FKBP12 (450 cpm/pmol) for 30 min at 37°C, as specified in the figure legends. CSR samples were incubated in CSR isolation buffer (10 mM imidazole-Cl, pH 7.4, 0.3 M sucrose, and 0.65 M KCl), whereas skeletal muscle SR fractions were incubated in imidazole homogenization medium, IHM (5 mM imidazole-Cl, pH 7.4, and 0.3 M sucrose), unless indicated otherwise. The different KCl concentrations present in these two buffers had no effect on specific or nonspecific binding of the FKBP isoforms to either SR fraction. Nonspecific binding (5-6 pmol/mg SR protein) was determined in the presence of 25-fold excess unlabeled FKBP12 or FKBP12.6 and, unless indicated otherwise, has been subtracted from total binding to give specific binding. Nonspecific binding did not change significantly with incubation time, temperature, or salt concentration (up to 1 M KCl). The free FKBP was separated from the bound 35 S-labeled FKBP isoform by diluting a 50-l sample (100 g protein) into 200 l of ice-cold buffer and immediately sedimenting the vesicles in a Beckman TL100.1 rotor at 95,000 rpm for 15 min at 4°C. The pellet was quickly washed, then resuspended in 0.2 ml distilled water (room temperature) and counted in 5 ml of CytoScint liquid scintillation mixture.
Preparation of Prelabeled SR Vesicles-SR vesicles (2.5 mg/ml) were prelabeled with 35 S-labeled FKBP by exchange as described previously (10) 35 S-Labeled FKBP12.6 was produced from the FKBP12.6-producing bacterial strain (13) using the identical inoculation, growth, and labeling conditions described for the production of 35 S-labeled FKBP12 (12) . The production of the bacterial lysate from the FKBP12.6-producing bacteria and the purification of 35 S-labeled FKBP12 was as described for unlabeled FKBP12.6 (13) . was diluted with 200 l of cold buffer used for incubation and sedimented at 95,000 rpm in the cold for 10 min in a TL 100.1 rotor. The 35 S-labeled FKBP in the pellet was measured by scintillation counting as described above.
Affinity Purification of RyR-2 Based upon Its Specific Association with FKBP12.6 -Affinity purification of RyR-2 from canine heart SR was performed by using GST/FKBP12.6 essentially as described previously (16) . CSR was diluted to 4 mg/ml with IHM buffer containing 0.6 M KCl and incubated with GST/FKBP12.6 or GST/FKBP12 (3 M) at 37°C for 30 min. The mixture was suspended in solubilization buffer (20 mM Tris-Cl, pH 7.4, 1.0 M NaCl, 0.2 mM phenylmethylsulfonyl fluoride, 2 mM dithiothreitol, and 2 g/ml leupeptin) and solubilized by the addition of a CHAPS-soybean lecithin mixture to a final concentration of 4% CHAPS and 2% soybean lecithin at a final concentration of 2.5 mg SR protein/ml (17) . Following incubation on ice for 10 min, the solubilized sample was centrifuged at 50,000 rpm in a Beckman TL100.2 rotor for 15 min at 4°C. The supernatant was diluted 4-fold to reduce the NaCl concentration to 0.25 M and the CHAPS-soybean lecithin concentrations to 1 and 0.5%, respectively. The diluted supernatant was then incubated in batch with Glutathione Sepharose 4B for 2 h at 4°C with gentle mixing. The suspension was centrifuged at 500 ϫ g for 5 min to sediment the resin. The resin was washed three times with 10 bed volumes of washing buffer (Na 2 HPO 4 , pH 7.4, 0.5 M KCl, 0.5% CHAPS, 2 g/ml leupeptin, and 2 mM dithiothreitol). After washing, the RyR⅐GST/FKBP12.6 complex bound to the matrix was eluted by incubation for 10 min at room temperature with 1 bed volume of elution buffer (50 mM Tris-Cl, pH 8.0, 0.5 M KCl, 0.5% CHAPS, 2 g/ml leupeptin, 2 mM dithiothreitol, and 0.1 M glutathione). The eluate was recovered after sedimentation of the resin as described above.
Estimation of FKBP12 Concentration in Canine Heart Cytosol-The concentration of FKBP12 in the cytosolic fraction of canine heart tissue was determined by both Scatchard analysis of 3 H-labeled FK816 drug binding and quantitative Western blot analysis of the cytosolic fraction as described previously (10) .
Single Channel Analysis-Single channel measurements of the cardiac CRC was recorded following fusion of CSR vesicles to painted lipid bilayers. SR vesicles were also pretreated with 5 M FK590 for 30 min at 37°C to remove FKBP12.6. Three different preparations were used in these studies. Planar lipid bilayers were formed by painting phospholipid (50 mg/ml PE:PS (1:1) in decane) across a 100-m hole separating cis and trans compartments of 1 ml each. The trans compartment contained 250 mM HEPES/Ca(OH) 2 (pH 7.4), which is equivalent to 52 mM Ca 2ϩ . The trans chamber was connected to the headstage of an EPC-7 patch clamp amplifier (List, Darmstadt, Germany) by a Ag/AgCl electrode and agar bridge (2% agar in 2 M KCl, 250 mM HEPES/Tris, pH 7.4) and clamped at 0 mV. The cis chamber was held at ground using a similar electrode. For fusion of CSR vesicles to the painted bilayer, 5 g protein were added to the cis chamber (containing 1 mM CsCl, 250 mM HEPES/Tris, pH 7.4, and 1 mM CaCl 2 ) with stirring. After fusion, the cis chamber was perfused with 10 volumes of 250 mM HEPES/Tris, pH 7.4, and the calculated free calcium concentration was adjusted to 2 M with 0.55 mM CaCl 2 and 1 mM HEDTA according to the programs of Fabiato (18) and Robertson and Potter (19) . HEDTA was used (apparent disso-
to buffer the free [Ca 2ϩ ] in our studies because it has much higher buffering capacity in the range of cardiac ryanodine receptor activation (EC 50 ϳ2 M). Stock solutions of FKBP12.6 in TSK column buffer (20 mM NaPO 4 , pH 6.8, 50 mM Na 2 SO 4 , 5 mM ␤-mercaptoethanol, 1 mM EDTA, and 0.5 mM phenylmethylsulfonyl chloride) were dialyzed versus HEPES-Tris, pH 7.4 (adjusted in the cold), because a component of the TSK buffer, likely the mercaptoethanol, was found to decrease the P o . Traces shown were recorded before, and 3 min after addition of 3 M FKBP12.6 to the bath with stirring for 30 s. For each condition, open probabilities were calculated for 5 min of recording time for six experiments (versus 3 min used by us previously). The longer sampling time is required to decrease variation of P o values due to modal changes in channel activity. Data were filtered through a 500 Hz low pass Bessel filter (model 902, Frequency Devices), digitized with the Digidata 1200 acquisition board (Axon Instruments), stored on optical disk (Maxoptic, Tahiti), and analyzed using pClamp6 (Axon Instruments) and Origin3 software (Microcal).
Ryanodine Binding-High affinity ryanodine binding is an index of the open state of the receptor (20) . FKBP-stripped CSR vesicles were prepared by drug treatment as described previously. After incubation, the control (ethanol-treated vesicles) and drug-treated vesicles were sedimented and resuspended in buffer containing 150 mM KCl, 200 mM HEPES/KOH (pH ϭ 7.0), 60 nM of [ 3 H]ryanodine, 1 mM HEDTA, and variable amounts of CaCl 2 to obtain free [Ca 2ϩ ] ranging from 0.05 M to 1 mM, as calculated by the IONS program (18) . The samples were incubated 2 h at room temperature (23-25°C). Ryanodine bound to the SR membranes was separated from unbound ryanodine by sedimentation (10 min at 95,000 rpm in a TL100.1 rotor) or by filtration of 100-l aliquots (50 g protein) through 0.22 m Millipore filters. The pellets were rinsed two times with buffer; transferred into vials; resuspended with 0.5 ml of solution containing 0.1% SDS, 1 mM EDTA, and 10 mM NaOH; and counted in 5 ml of liquid scintillation mixture. Specific binding of ryanodine was determined as the difference between total counts and nonspecific counts (10 M unlabeled ryanodine). Calcium Loading Assay-The net Ca 2ϩ loading rate of CSR was measured by spectrophotometry using antipyrilazo III as described previously (5, 21) . The calcium loading assay was carried out by adding 50 g of CSR vesicles (25 l) to 1 ml of assay solution containing 100 mM potassium phosphate, 0.5 mM antipyrilazo III, 0.5 mM MgCl 2 , and 1 mM ATP. These conditions were selected to optimize sensitivity to reagents that activate (caffeine) and block (ruthenium red) the cardiac CRC. Calcium levels were monitored by measuring the difference in absorbance between 710 and 790 nm with a diode array spectrophotometer (model 8451, Hewlett Packard, Sunnyvale, CA). Aliquots of 8 nmol CaCl 2 were added to the cuvette with stirring, producing Ca 2ϩ spikes. The Ca 2ϩ uptake rate from each experiment was calculated from the average uptake rate of two pulses of Ca 2ϩ .
RESULTS AND DISCUSSION

Soluble FKBP12.6 Exchanges with FKBP Bound to RyR-2 of CSR
The exchange of soluble 35 S-labeled FKBP12.6 with the cardiac CRC complex of canine heart SR is time-and temperaturedependent (Fig. 1A) . The exchange is represented as specific binding (i.e. total minus nonspecific) of 35 S-labeled FKBP12.6. These results are similar to the exchange reaction described between soluble 35 S-labeled FKBP12 with skeletal muscle TC (10) . That is, the reaction rate is enhanced with increasing temperature from 0 to 37°C with a t1 ⁄2 at 37°C of 5-10 min. Although the rate of exchange is significantly reduced at 0 -4°C, the exchange of 35 S-labeled FKBP12.6 with CSR occurs somewhat more rapidly in the cold than the exchange of 35 S-labeled FKBP12 with skeletal muscle TC (10). The exchange process in CSR is likewise concentration-dependent (Fig. 1B) . Scatchard analysis (data not shown) of the specific binding data obtained from the exchange isotherm yields a single straight line consistent with one type of binding with an apparent dissociation constant of 156 Ϯ 43 nM and an apparent B max value of 23.1 Ϯ 3.0 pmol FKBP12.6 binding site/mg CSR protein (n ϭ 3). The B max value for high affinity [ 3 H]ryanodine binding to the same SR preparations is 5.7 pmol/mg SR protein (data not shown). Since the tetrameric cardiac CRC complex has just a single high affinity ryanodine binding site under these assay conditions (20) , the stoichiometry of FKBP12.6 binding sites per cardiac CRC is calculated from the ratio of B max values for FKBP12.6 and high affinity ryanodine binding. Our results yield a stoichiometry of 4.1 FKBP12.6 binding sites per cardiac CRC. This is essentially the same value as that determined for the number of FKBP12 binding sites per SkM CRC (5, 10) . The data in Fig. 1, A and B, can be used to calculate the percentage of unoccupied FKBP12.6 binding sites in canine heart SR vesicles. The rapid binding in the cold (i.e. the zero time-point in Fig. 1A ) of 35 S-labeled FKBP12.6 to CSR vesicles estimates the concentration of unoccupied binding sites since the direct binding of FKBP is rapid in the cold, whereas the exchange reaction is precluded. We estimate the concentration of unoccupied FKBP12.6 binding sites to be about 4 pmol/mg SR protein (Fig.  1A) , whereas the concentration of occupied plus unoccupied binding sites (B max ) is 23.1 pmol/mg (Fig. 1B) . Therefore, in comparison to the 6% unoccupancy calculated for rabbit skeletal muscle TC, 17% of the total FKBP12.6 binding sites in dog CSR vesicles appear to be unoccupied.
The time dependence for exchange of either S-labeled FKBP12.6 from prelabeled CSR. CSR vesicles (2.5 mg/ml) were prelabeled with 35 S-labeled FKBP12.6 (25.4 Ϯ 2.4 pmol/mg CSR protein) by the exchange methodology described previously (10) with the modifications noted under "Experimental Procedures." The prelabeled CSR were incubated at 37°C for 30 min in the presence of the indicated concentrations of unlabeled: f, FKBP12.6; Ⅺ, GST/FKBP12.6; å, FKBP12; Ç, GST/FKBP12; and q, FK590. Following incubation, 35 Slabeled FKBP bound to the SR vesicles was determined as described above. The five displacement curves shown in the figure were drawn directly through the data points. Each experiment was performed two times with two different preparations with each point in duplicate, with similar results. B, displacement of 35 S-labeled FKBP12 prelabeled SkM SR. SkM SR (R 3 fraction) vesicles (2.5 mg/ml) were prelabeled with 35 S-labeled FKBP12 (38.0 pmol/mg), and displacement curves were generated as described in A. Each data point is the average of triplicates obtained from a single SR preparation. The displacement curves with FK590 and unlabeled FKBP12 (same symbols as in A) are similar to previously published 35 S-labeled FKBP12 displacement curves from prelabeled SkM TC vesicles (10). curves in Fig. 2A show that (Fig. 2B) .
Competition Binding Studies
The preference of the CSR for FKBP12.6 was confirmed in competitive binding studies. The vesicles were first stripped of their endogenous FKBP by incubation with FK590 as described previously and isolated by centrifugation, which separates the FKBP-stripped vesicles in the pellet from the soluble FKBP⅐drug complex that remains in the supernatant (5) The binding of FKBP to FKBP-stripped vesicles was then performed in the cold for 3 min, a condition that precludes the exchange phenomenon (Fig. 1A) . The bar graph in Fig. 3 shows that FKBP-stripped CSR vesicles bind FKBP12.6 selectively (compare bar 1 versus bar 2) . Furthermore, the 35 S-labeled FKBP12.6 binding is competed for by unlabeled FKBP12.6 but not unlabeled FKBP12 (Fig. 3, bar 3 versus bar 4) . Conversely, FKBP-stripped skeletal muscle TC vesicles bind comparable amounts of either 35 S-labeled FKBP12 or 35 S-labeled FKBP12.6 (Fig. 3, bars 7 and 8) , which are effectively competed for by either unlabeled FKBP (10, 11, 16) .
The FKBP in CSR Is Specifically Associated with the RyR-2
To confirm that 35 S-labeled FKBP12.6 binding to CSR reflects specific association of FKBP12.6 with the cardiac CRC (Fig. 1) , RyR-2 was affinity purified from canine CSR vesicles based on its specific association with FKBP12.6. First, the endogenous FKBP in CSR was replaced (ϳ85%) with the GST/ FKBP12.6 fusion construct using either the dissociation/reconstitution or exchange methodology, with similar results obtained by either method. The experiment shown in Fig. 4 used the exchange methodologies. The mixture of CSR vesicles with excess GST/FKBP was solubilized with CHAPS, and the cardiac CRC⅐GST/FKBP12.6 complex was affinity purified by glutathione-Sepharose chromatography (Fig. 4) . Fig. 4, lanes 1-4 , monitors the purification of RyR-2 as observed by Coomassie Blue stained SDS-polyacrylamide gel electrophoresis analysis. The protein profiles of CSR (Fig. 4, lane 1) can be compared with the applied sample (Fig. 4, lane 2) , which contains the mixture of CHAPS-solubilized SR with excess GST/FKBP12.6. A band referrable to the GST/FKBP12.6 fusion construct (ϳ40 kDa) is evident in the applied sample which, as expected, is essentially absent in the column flow through (Fig. 4, lane 3) . Bands referable to both the GST/FKBP12.6 and RyR-2 are clearly evident in the glutathione eluate (Fig. 4, lane 4) . The high molecular weight bands referable to RyR-2 were further identified by Western blot analysis using sequence-specific an- 
FIG. 4.
Affinity purification of RyR-2 from canine heart SR based upon its specific association with FKBP12.6. The affinity purification procedure (16) is described under "Experimental Procedures." Electrophoresis was carried out on 7.5% SDS-polyacrylamide gel, and the RyR was detected by staining with Coomassie Blue (A) or by Western blot analysis using antibody specific for RyR-2 (B). Lane 1, canine heart SR; lanes 2 and 5, CHAPS-solubilized CSR incubated with GST/FKBP12.6 and GST/FKBP12, respectively; lanes 3 and 6, the supernatant after absorption of the GST/FKBP12.6 and GST/FKBP12 by Glutathione-Sepharose 4B, respectively; lanes 4 and 7, glutathione eluates from the affinity chromatography; lane 8, cardiac RyR-2 purified by sucrose gradient centrifugation. For Western blot analysis (B), the amount of sample loading was one-half of that for Coomassie Blue staining. Positions of the molecular weight standard (Bio-Rad) are indicated to the left. tiserum raised against RyR-2 (Fig. 4B, lane 4) . By contrast, the cardiac CRC is not purified when GST/FKBP12 is used in place of GST/FKBP12.6 (Fig. 4, lanes 5-7) , although the GST/ FKBP12 construct was clearly adsorbed to and eluted from the column with glutathione (Fig. 4, lane 7) . On the other hand, RyR-1 from skeletal muscle TC can be purified using either GST/FKBP12 or GST/FKBP12.6 (16) . These studies confirm that: 1) the binding of FKBP to the SR vesicles is specific to the RyR; 2) RyR-2 has specificity for binding FKBP12.6; and 3) RyR-1 binds both FKBP12 and FKBP12.6.
Detection and Estimation of FKBP Isoforms in the Cytosol of Heart and Skeletal Muscle
Northern blot analysis detects the presence of mRNA for both FKBP isoforms, albeit the level of message for FKBP12 is much higher in both tissues (13) . It is, therefore, not surprising that only FKBP12 and not FKBP12.6 can be readily detected in the cytosol of the tissues by Western blot analysis (Ref. 10 and this study). From both [ 3 H]FK816 binding isotherms and quantitative Western blot analysis, we estimate the concentration of FKBP12 to be about 3 M, whereas the concentration of FKBP12.6 is below the limit of detection in our assays. The specificity of binding of RyR-2 for FKBP12.6 found in this study explains, at least in part, our observation that RyR-2 is isolated from canine heart SR as a complex with FKBP12.6, although only FKBP12 is detectable in the cytosol. On the other hand, RyR-1 can bind either FKBP12 isoform with comparable affinity. It appears that RyR-1 is isolated as a complex with FKBP12 primarily because of the large excess of FKBP12 over the concentration of FKBP12.6 in muscle cytosol.
Effect of Removal of FKBP12.6 from RyR-2 on Channel Function
Single Channel Measurements-CSR depleted of FKBP12.6 were reconstituted into planar lipid bilayers (Fig. 5a ). The removal of FKBP12.6 (drug-treated or FKBP-stripped 3 ) did not significantly change the open probability (P o ) of RyR-2 as compared with untreated controls. Addition of FKBP12.6 to FKBPdepleted channels did not alter the open probability, and subsequent perfusion to wash out excess FKBP12.6 was without effect. These studies with heart SR are in marked contrast with those of skeletal muscle SR, where removal of FKBP12 greatly FIG. 5 . Effect of removal of FKBP12.6 on cardiac CRC activity. a, CSR were incorporated into planar bilayers, and channel activity was measured (see "Experimental Procedures"). The calculated free calcium ion concentration in the cis chamber was adjusted to 2.0 M (see "Experimental Procedures") following the fusion of the vesicle(s) to the phospholipid bilayer. Similar results were obtained for drug-treated and FKBP-stripped CSR in the three studies shown (a-c). 3 Single channel recordings are shown for: a.i., CSR stripped of FKBP12.6 or drug-treated CSR; a.ii., the same channel after adding 2 M FKBP12.6 to the cis-side of the membrane, which is equivalent to the cytosolic face of the channel; and a.iii., after washout of excess FKBP12.6 by perfusion of the bilayer solution during 4 min at a rate of 4 ml/min with 250 mM HEPES/Tris, pH 7.4, solution. The free Ca 2ϩ was again buffered to 2 M. The closed state of the channel is indicated by the horizontal line on the left. Channel activity was essentially the same for the three conditions, indicating that re-addition of FKBP12.6 to FK590 treated channels was without effect. Average P o values were 0.31 Ϯ 0.06, 0.38 Ϯ 0.07, and 0.30 Ϯ 0.07 for n ϭ 6 experiments for conditions i, ii, and iii, respectively; the P o for untreated CSR was 0.36 Ϯ 0.05 (n ϭ 25). b, Ca 2ϩ dependence of ryanodine binding to control (f) and FK590 stripped (q) CSR vesicles. Specific ryanodine binding at [Ca 2ϩ ] ranging from 0.01 to 1000 M was carried out as described under "Experimental Procedures." Data are averages of triplicate determinations from n ϭ 5 different preparations; bars, S.D. FK590 produced no significant differences on ryanodine binding at any Ca 2ϩ level. c, Ca 2ϩ loading of CSR vesicles for control and drug-treated vesicles. ATP (1 mM) was added to activate Ca 2ϩ uptake; then two successive additions of 8 nmol of CaCl 2 produced Ca 2ϩ spikes. The rate of Ca 2ϩ uptake was identical in both conditions. Average values from three different preparations were 103 Ϯ 7 and 101 Ϯ 7 nmol Ca 2ϩ /min⅐mg for control and drug-treated SR vesicles, respectively.
increased the P o of RyR-1 (5-7 ] dependence of ryanodine binding to CSR vesicles was compared in control versus drug-treated or FKBP-stripped vesicles in Fig. 5b . Plateau values for maximal ryanodine binding were similar in each preparation, 3.0 Ϯ 0.5 and 2.8 Ϯ 0.6 pmol/mg SR protein (n ϭ 4) for control versus FK590-treated vesicles. Furthermore, ryanodine binding over a wide range of free [Ca 2ϩ ] was also essentially the same in control versus drug-treated CSR (Fig. 5b) . TC vesicles from skeletal muscle were used as positive control for FK590 effects on [ 3 H]ryanodine binding. Treatment of this preparation with drug enhanced ryanodine binding about 2-fold (n ϭ 3). 4 Ca 2ϩ Loading-Ca 2ϩ loading of SR can be used as a macroscopic measure of CRC activity (5, 10, 21) . That is to say, activation of the CRC introduces a leak for Ca 2ϩ so that the net Ca 2ϩ uptake rate is reduced. As shown in Fig. 5c , we found no significant difference in the Ca 2ϩ loading rate in control versus drug-treated CSR. Removal of FKBP in CSR did not alter its response to diagnostic drugs. For example, the rate of Ca 2ϩ loading was nearly doubled (1.71 Ϯ 0.15, n ϭ 5) by 10 M ruthenium red (a CRC blocker) and reduced to one-half (0.54 Ϯ 0.04, n ϭ 4) by 1 mM caffeine (a CRC agonist), also indicating that the conditions were suitable to observe changes in CRC activity. Finally, we found no effect by treatment of CSR with 5 M rapamycin (n ϭ 3) or by adding 2 M FKBP12.6 to either control or FK590-treated samples (n ϭ 4) (data not shown). The studies with CSR contrast with our previous studies for skeletal muscle TC, where removal of FKBP12 from RyR-1 with drug resulted in a 2-fold decrease in Ca 2ϩ loading and profound activation of channel activity, which could be overcome by the addition of excess of FKBP12 (5) (6) (7) .
In this study, skeletal muscle TC were used as positive control for FK590, rapamycin, and FKBP isoforms. For skeletal muscle, either FKBP12.0 or FKBP12.6 helps to maintain the RyR-1 in the closed state. However, for the cardiac RyR-2, we do not detect any differences in channel properties using three different approaches to assess cardiac CRC function.
What is the Role of FKBP12.6 in the Heart?-The cardiac CRC (RyR-2) is associated with the novel FKBP12.6, whereas the skeletal muscle CRC (RyR-1) is associated with FKBP12. The stoichiometry of the dog heart CRC is approximately four FKBP⅐CRC complex, i.e. one FKBP per RyR protomer, as for skeletal muscle. Thus, the native CRC of dog heart and skeletal muscle are hetero-oligomeric complexes consisting of four RyR protomers and four FKBPs. However, removal of FKBP from dog heart SR by drug treatment does not alter the sensitivity of the channel to Ca 2ϩ -induced activation, as we have observed in skeletal muscle SR using three different protocols, single channel analysis (6), Ca 2ϩ loading rate (22) , and ryanodine binding (this study). The lack of activation in heart by removal of FKBP represents an important difference between RyR-1 and RyR-2. We cannot preclude that the association of FKBP12.6 with cardiac CRC modifies its behavior, albeit in a manner not yet discerned. However, the modulation readily observed in skeletal muscle is not observed in the heart.
